AMRN
AmarinDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Vascepa sales stabilize, margins expand and legal/regulatory overhangs ease, restoring analyst confidence and lifting the stock above the anchor toward the bull target.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +16.3.
What can break
Adverse litigation or patent rulings
Momentum
18
Value
57
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.82 · Bull $20.57 · Bear $11.07
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-11 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $12.00
Why
Momentum18 · Δ7d -6.6
Value57 · Δ7d +16.3
Sentiment60 · Δ7d +3.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
18
26% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
-37.9
Value
57
39% active weight
Current posture
7d trendImproving
Δ7d
+16.3
Δ21d
+16.2
Sentiment
60
34% active weight
Current posture
7d trendImproving
Δ7d
+3.0
Δ21d
+11.8
Why this grade
Composite grade D. Momentum 18.3 / Value 57.4 / Sentiment 60.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$292.46M
Beta
0.84
Shares Out
20.98M
P/E (TTM) · Derived
-7.4
P/S (TTM)
1.24
P/FCF (TTM) · Derived
-3.81
Rev YoY
+6.8%
EPS YoY
-34.3%
Gross Margin
+51.1%
Op Margin
-42.5%
Net Debt
-$296.71M
Current Ratio
3.48
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology